Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Decides On Use And Dose For Methotrexate And Botox

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare's Panel on Drugs to Children approved a working group paper on the use and dosage of two drugs: MTX (methotrexate) 2 mg manufactured by Wyeth and imported by Takeda, and GlaxoSmithKline's Botox (botulinum toxin type A). The recommended dose for MTX is 4 mg-10 mg within a week, and for Botox is 4 units per kilogram of a patient's weight, and with an administration interval of 3 month and maximum dose of 200 units. MTX treats juvenile idiopathic arthritis, a whole body chronic infection usually occuring in childhood. Botox treats equinus foot, a deformity associated with cerebral palsy. The panel will report the recommendations to MHLW's Food and Drug Council and request the companies to change the applications accordingly. (Click for more-Japanese language

You may also be interested in...

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

For Emergency Use, US FDA May Visit Rather Than Inspect COVID-19 Vaccine Manufacturing Sites

Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts